West Pharmaceutical Services, Inc. (WST) Q3 2026 earnings results
West Pharmaceutical Services, Inc. (WST) reported Q3 2026 results on Oct 29, 2026, 6:00:00 AM ET: adjusted EPS $2.66 vs. $2.20 expected (beat by 21.1%); revenue $874.50M vs. $826.55M expected (beat by 5.8%). Outlook: Full-year 2026 net sales guidance increased to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance increased to $9.38 to $9.48.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $2.66 | $2.20 | Beat by 21.1% |
| Revenue | $874.50M | $826.55M | Beat by 5.8% |
Analyst estimate: the average forecast before the release.
Source
Figures from the press release, released Oct 29, 2026, 6:00:00 AM ET. Nexqual published them 2 min 10 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 8.7% from $804.60M.
Stock reaction
The results came out before the market opened. WST closed at $416.67 on October 29, 2026, up 3.2% from its $403.64 close on October 28, 2026 before the results.
Questions and answers
Did West Pharmaceutical Services, Inc. beat earnings expectations?
Yes. West Pharmaceutical Services, Inc. reported adjusted EPS of $2.66 against an average analyst estimate of $2.20 (beat by 21.1%), and revenue of $874.50M against $826.55M expected (beat by 5.8%).
What were West Pharmaceutical Services, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $2.66 and revenue of $874.50M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 8.7% from $804.60M.
When did West Pharmaceutical Services, Inc. report Q3 2026 earnings?
Oct 29, 2026, 6:00:00 AM ET, in a company press release.
How did WST stock react to the earnings?
The results came out before the market opened. WST closed at $416.67 on October 29, 2026, up 3.2% from its $403.64 close on October 28, 2026 before the results.
What did West Pharmaceutical Services, Inc. say about its outlook?
Full-year 2026 net sales guidance increased to $3.41 billion to $3.42 billion and adjusted-diluted EPS guidance increased to $9.38 to $9.48.
More on WST
WST stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings October 29, 2026.
Source: company earnings press release, Nexqual Earnings Flash. Built October 29, 2026 at 23:07 UTC. Not investment advice.
Data source: Nexqual. Last updated: October 29, 2026 at 23:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt